Leung J T
Adelaide Radiotherapy Centre, South Australia, Australia.
Australas Radiol. 1996 Nov;40(4):430-3. doi: 10.1111/j.1440-1673.1996.tb00441.x.
Thymoma is a rare disorder and the treatment of invasive disease is controversial. Seventeen patients with pathologically confirmed thymoma were treated at Royal Prince Alfred Hospital between 1982 and 1993. There were two stage 1 patients, four stage 2 patients and 11 stage 3 patients. Five patients had total resection, eight patients had subtotal resection and four patients had biopsy only. All patients received radiotherapy, with the median dose being 50 Gy. The median survival was 117 months and the 5-year survival was 69%. This was influenced by stage of disease and extent of surgical resection. The local control was 76%. Three patients developed distant metastatic disease. There were insufficient numbers to determine a dose response to radiotherapy. Patients with invasive disease should continue to have postoperative radiotherapy. A brief review of the literature is made.
胸腺瘤是一种罕见疾病，侵袭性疾病的治疗存在争议。1982年至1993年间，皇家阿尔弗雷德王子医院对17例经病理确诊的胸腺瘤患者进行了治疗。其中1期患者2例，2期患者4例，3期患者11例。5例患者接受了根治性切除，8例患者接受了次全切除，4例患者仅接受了活检。所有患者均接受了放疗，中位剂量为50 Gy。中位生存期为117个月，5年生存率为69%。这受到疾病分期和手术切除范围的影响。局部控制率为76%。3例患者发生远处转移。由于病例数不足，无法确定放疗的剂量反应。侵袭性疾病患者术后应继续接受放疗。本文对相关文献进行了简要综述。
